No Prescription |
 |
 | ||
|
Prulifloxacin (Pruquin) |
|
| ||
No Prescription » Anti Bacterial » Prulifloxacin (Pruquin) Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Buy Prulifloxacin (Pruquin) and other Anti Bacterial products online at Medstore. Buy Online at Medstore - Click Here!
About Prulifloxacin (Pruquin): Product Type: Anti Bacterial Brand name: Prulifloxacin Generic name: Pruquin Prulifloxacin has a proven broad and powerful antibacterial action on both Gram positive and Gram negative bacteria in the treatment of respiratory and uro-gynecological infections. Its antibacterial action proved to be highly effective both during the first infective episodes as well as in complicated and chronic infections. Prulifloxacin has a chemical structure that allows its absorption from the gastrointestinal tract and can therefore be administered orally. Its half-life is quite long and the molecule remains in the bloodstream for about 11 hours. This characteristic allows a 600-mg tablet to be administered only once a day for a very convenient dosing. The active metabolite of prulifloxacin (ulifloxacin) is mostly cleared in an unchanged form through the urinary tract; this allows the drug to be consistently active until its clearance. In clinical trials side effects mostly included gastrointestinal disorders reported by only 4% of patients and almost never requiring the discontinuation of treatment. “Adequate in males because of its spectrum prulifloxacin is the ideal antibiotic in women: it can eradicate pathogens while respecting the residual population that should be saved in order to prevent relapses and complications in the female gender” (GIMMOC Volume IX Quaderno 2 2005). Prulifloxacin in conclusion is effective and tolerable in the treatment of respiratory and uro-gynecological infections while respecting the lactobacillus vaginal microflora reducing the risk of vaginitis (mostly due to Candida albicans) following the antibiotic therapy. Prulifloxacin the prodrug of ulifloxacin is a broad-spectrum oral fluoroquinolone antibacterial agent. After absorption prulifloxacin is metabolised by esterases to ulifloxacin. The drug has a long elimination half-life allowing once-daily administration. A Ulifloxacin is generally more active in vitro than other fluoroquinolones against a variety of clinical isolates of Gram-negative bacteria including community and nosocomial isolates of Escherichia coli Klebsiella spp. Proteus Providencia and Morganella spp. Moraxella catarrhalis and Haemophilus spp. The activity of ulifloxacin against Pseudomonas aeruginosa varies between countries. A Gram-positive organisms including meticillin- or oxacillin-susceptible Staphylococcus aureus Enterococcus spp. and Italian community isolates of Streptococcus pneumoniae are susceptible to ulifloxacin. Activity against Spanish strains of S. pneumoniae is moderate. A In well designed clinical trials good clinical and bacteriological efficacy (similar to that of ciprofloxacin amoxicillin/clavulanic acid or pefloxacin) was seen with prulifloxacin 600mg once daily for 10 days in patients with acute exacerbations of chronic bronchitis or complicated lower urinary tract infections (UTIs) and with single-dose prulifloxacin 600mg in acute uncomplicated lower UTIs. A Prulifloxacin was generally well tolerated in clinical trials with a similar tolerability profile to that of ciprofloxacin. Generic Prulifloxacin (Pruquin) Prulifloxacin (Pruquin) 600mg 10 tabs 600mg 15 tabs 600mg 20 tabs 600mg 25 tabs 600mg 5 tabs Pruquin Prulifloxacin
View more Anti Bacterial No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
